Stockreport

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]

Astria Therapeutics, Inc.  (ATXS) 
PDF -- STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of Atopic Dermatitis, on Track for Expected IND Submission by Year-End 2024 and Phase 1a Initiation [Read more]